TIDMHIK 
 
RNS Number : 4480V 
Hikma Pharmaceuticals Plc 
02 November 2010 
 

 
 
                    Hikma Pharmaceuticals PLC - LTIP Awards 
 
LONDON, 2 November 2010: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) 
announces that the Remuneration Committee has made the following nil-cost awards 
under the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the "LTIP") 
to Persons Discharging Managerial Responsibility ("PDMRs") of the Company. 
 
Awards under the LTIP were made on 2 November 2010 at a price of 795.5 pence per 
ordinary share as follows:- 
 
+---------------------------------+---------------------------------+ 
| Name of Director                |           Number of LTIP Shares | 
| Said Darwazah                   |                         105,000 | 
+---------------------------------+---------------------------------+ 
| Mazen Darwazah                  |                          70,000 | 
+---------------------------------+---------------------------------+ 
 
The shares subject to the LTIP awards will only be released to the participants 
in three years time, subject to their continued employment and the satisfaction 
of the comparative Total Shareholder Return ("TSR"), sales growth, earnings per 
share ("EPS") growth and return on invested capital ("ROIC") performance 
targets. Half of the award is subject to TSR against the Comparator Group and 
requires at least upper quartile performance to vest in full. The remaining half 
is split equally between the financial targets and requires sales growth of 13%, 
EPS growth of 20% and ROIC of 12% to vest in full. Each target is measured 
individually and is independent of the other targets. 
 
                                    - ENDS - 
 
Enquiries: 
 
Hikma Pharmaceuticals PLC 
Henry Knowles                                                 +44 20 7399 2760 
Company Secretary 
 
Susan Ringdal                                                  +44 20 7399 2760 
Investor Relations Director 
 
About Hikma 
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on 
developing, manufacturing and marketing a broad range of both branded and 
non-branded generic and in-licensed products.  Hikma's operations are conducted 
through three businesses: "Branded", "Injectables" and "Generics" based 
principally in the Middle East and North Africa ("MENA") region, where it is a 
market leader, the United States and Europe.  In 2009, Hikma achieved revenues 
of $637 million and profit attributable to shareholders of $78 million.  For 
news and other information, please visit www.hikma.com. 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RDSBGBDBGSGBGGD
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.